Coya Therapeutics Q2 Cash Runway Past ALS Data, Fast Track Designation Secured
COYA sits 30% above its 52-week low of $3.71.
Summary
Coya Therapeutics reported Q2 2026 results with $43.2M in cash, funding operations past the ALSTARS Phase 2 ALS topline readout expected in Q1 2027. Revenue was $243,745, and net loss widened to $6.6M, or 28 cents per share, from $6.1M a year ago, driven by higher R&D spending of $5.0M on the ALS trial. Enrollment is on track to complete in 2H 2026, and the first cohort has entered the 24-week blinded extension. The FDA granted Fast Track Designation for COYA 302 in ALS, potentially accelerating regulatory review. A Phase 2 study in frontotemporal dementia is planned to start in coming months. The cash position and clinical progress reduce near-term financing risk ahead of key data catalysts.
At the time of this announcement, COYA was trading at $4.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.8M. The 52-week trading range was $3.71 to $7.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.